DR. JOEL MATTHEW MICHALSKI MD PHD NPI 1437599248

NPI Details

DR. Joel Matthew Michalski, MD, PHD is an internal medicine in Omaha, NE with 13 years of experience. The provider is a physician who provides long-term, comprehensive care in the office and the hospital, managing both common and complex illness of adolescents, adults and the elderly. Internists are trained in the diagnosis and treatment of cancer, infections and diseases affecting the heart, blood, kidneys, joints and digestive, respiratory and vascular systems. They are also trained in the essentials of primary care internal medicine, which incorporates an understanding of disease prevention, wellness, substance abuse, mental health and effective treatment of common problems of the eyes, ears, skin, nervous system and reproductive organs. DR. Joel Matthew Michalski, MD, PHD NPI is 1437599248. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF NEBRASKA COLLEGE OF MEDICINE
Graduation Year:2013

The provider's business location address is:

982055 NEBRASKA MEDICAL CTR
OMAHA, NE
ZIP 68198-055
Phone: (402) 559-7268

The NPI 1437599248 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Magnesium level (HCPCS:83735)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Ferritin (blood protein) level (HCPCS:82728)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Cortisol (hormone) measurement, total (HCPCS:82533)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Unclassified drugs (HCPCS:J3490)
• Injection of drug or substance into vein (HCPCS:96374)
• Liver function blood test panel (HCPCS:80076)
• Collection of blood sample from implanted device (HCPCS:36591)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen (HCPCS:87635)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Influenza vaccine split virus, preservative free (HCPCS:90662)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Urinalysis, manual test (HCPCS:81002)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Drawing of blood for a medical problem (HCPCS:99195)
• Detection test by immunoassay with direct visual observation for influenza virus (HCPCS:87804)
• Beta-2 microglobulin (protein) level (HCPCS:82232)

The enumeration date for this NPI number is 6/26/2013 and was last updated on 6/26/2013.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: